- Home
- BXP vs EXAS Comparison
BXP vs EXAS Comparison
Compare BXP & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXP
- EXAS
- Stock Information
- Founded
- BXP 1970
- EXAS 1995
- Country
- BXP United States
- EXAS United States
- Employees
- BXP N/A
- EXAS N/A
- Industry
- BXP Real Estate Investment Trusts
- EXAS Medical Specialities
- Sector
- BXP Real Estate
- EXAS Health Care
- Exchange
- BXP Nasdaq
- EXAS Nasdaq
- Market Cap
- BXP 11.7B
- EXAS 10.2B
- IPO Year
- BXP 1997
- EXAS N/A
- Fundamental
- Price
- BXP $77.77
- EXAS $53.59
- Analyst Decision
- BXP Hold
- EXAS Strong Buy
- Analyst Count
- BXP 16
- EXAS 22
- Target Price
- BXP $75.63
- EXAS $67.38
- AVG Volume (30 Days)
- BXP 1.8M
- EXAS 2.7M
- Earning Date
- BXP 10-28-2025
- EXAS 11-04-2025
- Dividend Yield
- BXP 5.04%
- EXAS N/A
- EPS Growth
- BXP N/A
- EXAS N/A
- EPS
- BXP 0.03
- EXAS N/A
- Revenue
- BXP $3,410,208,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- BXP $2.65
- EXAS $16.68
- Revenue Next Year
- BXP $2.56
- EXAS $12.08
- P/E Ratio
- BXP $2,798.05
- EXAS N/A
- Revenue Growth
- BXP 2.91
- EXAS 12.55
- 52 Week Low
- BXP $54.22
- EXAS $38.81
- 52 Week High
- BXP $90.11
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- BXP 63.80
- EXAS 60.65
- Support Level
- BXP $71.19
- EXAS $52.11
- Resistance Level
- BXP $79.33
- EXAS $56.52
- Average True Range (ATR)
- BXP 2.12
- EXAS 1.70
- MACD
- BXP 0.31
- EXAS 0.18
- Stochastic Oscillator
- BXP 80.86
- EXAS 71.33
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.